Skip to main content
. 2024 Mar 12;20(8):1046–1054. doi: 10.1200/OP.23.00563

FIG 1.

FIG 1.

Evolving neoadjuvant treatment of HER2-positive breast cancer. Blue, standard of care; Green, investigational; aStudy name. C, carboplatin; ET, endocrine therapy; H, trastuzumab; HER2, human epidermal growth factor receptor 2; P, pertuzumab; T, docetaxel; TDM1, trastuzumab-DM1.